Making an unwavering commitment to support people with serious medical conditions
Our track record of discovery, development and commercialization of important therapies includes Brovana® (arformoterol tartrate), Latuda® (lurasidone HCl), and Aptiom® (eslicarbazepine acetate). Our approved therapies also include Utibron® Neohaler® (indacaterol and glycopyrrolate) Inhalation Powder, Seebri® Neohaler® (glycopyrrolate) Inhalation Powder, Arcapta® Neohaler® (indacaterol) Inhalation Powder and Lonhala® Magnair® (glycopyrrolate) Inhalation Solution.
Sunovion has a robust portfolio and is expanding leadership in treatments for psychiatric, neurologic and respiratory conditions.
Through our pharmaceutical research and collaborations, we have had several therapies approved by the U.S. Food and Drug Administration (FDA), including: